---
title: "Veraxa Biotech partners with Ardigen on AI-enabled drug discovery for BiTAC pipeline"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/292477238.md"
description: "Veraxa Biotech has partnered with Ardigen to apply AI tools to its BiTAC pipeline for oncology. The collaboration aims to improve the selection of dual cancer targets for conditionally active T cell engagers, potentially expanding to antibody-drug conjugates. This strategy utilizes an 'AND-gate' approach to reduce on-target, off-tumor toxicity by activating only when two targets co-express on cancer cells. Initial efforts focus on AI models integrating preclinical and clinical datasets to identify synergistic target pairs."
datetime: "2026-07-13T11:00:57.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/292477238.md)
  - [en](https://longbridge.com/en/news/292477238.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/292477238.md)
generator: "portal-rs"
---

# Veraxa Biotech partners with Ardigen on AI-enabled drug discovery for BiTAC pipeline

-   Veraxa Biotech entered a collaboration with Ardigen to apply AI tools to its BiTAC pipeline in oncology. \* Work targets improved selection of dual cancer targets for conditionally active T cell engagers, with potential expansion to antibody-drug conjugates. \* Strategy aims to reduce on-target, off-tumor toxicity by using an “AND-gate” approach that activates only when two targets co-express on cancer cells. \* Initial focus includes AI models to integrate industry preclinical and clinical datasets to identify synergistic target pairs and refine program design. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Veraxa Biotech AG published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607130700OMX\_\_\_\_\_CNEWS\_EN\_GNW1001212497\_en) on July 13, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)

### Related Stocks

- [VRXA.US](https://longbridge.com/en/quote/VRXA.US.md)

## Related News & Research

- [Veraxa Biotech files Form 3 for Interim CFO Carl von Halem](https://longbridge.com/en/news/296530272.md)
- [Veraxa Biotech files first BiTAC-related patent applications for cancer therapy platforms](https://longbridge.com/en/news/294550628.md)
- [Regeneron Stock (REGN) Buckling as Shareholders Sue Over Cancer Drug Claims](https://longbridge.com/en/news/296616209.md)
- [AI isn’t close to curing cancer. This startup says it knows what it will take.](https://longbridge.com/en/news/296352961.md)
- [iSpecimen ships hundreds of cancer blood specimens for international research order within three weeks](https://longbridge.com/en/news/296531044.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**